A November 2025 case series reported that two patients with chronic atrophic gastritis (CAG) — one post-H. pylori, one autoimmune — showed histological improvement after 12 months on zinc L-carnosine (79 mg/day). Both moved backward on OLGA staging, with improved pepsinogen I, reduced gastrin-17, and symptom relief.
This commentary sets out the findings honestly: two uncontrolled, unblinded cases cannot separate a drug effect from regression to the mean or biopsy sampling variance. It is hypothesis-generating, not practice-changing. What earns it attention is mechanistic plausibility — zinc L-carnosine's site-specific anti-inflammatory and antioxidant action, and its effect on gastrin-17 signalling implicated in gastric epithelial transition.
The piece situates zinc L-carnosine among other agents studied for reversing precancerous gastric change (folic acid, vitamin C, L-cysteine), and closes with practical guidance: consider it as an adjunct to standard care — never a substitute for H. pylori eradication and surveillance — within the studied dose range, with attention to copper status and drug-timing interactions.
Download the detailed case study
